Learning Series: Maximizing the Potential in ALK+ NSCLC

To address educational gaps in community oncology regarding the diagnosis, treatment, and management of patients with ALK-positive metastatic non-small cell lung cancer (ALK+ mNSCLC).
To improve outcomes of ALK inhibitor-based treatments through effective management of adverse events, including timely identification, dose modifications and other innovative strategies.
To assist oncologists in assessing and managing specific adverse events related to ALK tyrosine kinase inhibitors (ALK TKls): for example, weight gain, neurocognitive effects and other AEs of significance.
To prepare patients and care partners for ALK inhibitor therapy to evaluate tolerability and implement appropriate therapy management regimens.